William M. Crist
St. Jude Children's Research Hospital
180 Papers
3.8K Citations
William M. Crist is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Acute lymphocytic leukemia & Rhabdomyosarcoma. The author has an hindex of 63, co-authored 180 publications. Previous affiliations of William M. Crist include University of Alabama at Birmingham & University of Pittsburgh.
Chat about Author
Papers
Predominance and characteristics of Burkitt lymphoma among children with non-Hodgkin lymphoma in northeastern Brazil
John T. Sandlund,T. Fonseca,T. Leimig,L. Verissimo,Raul C. Ribeiro,V. Lira,Costan W. Berard,John W. Sixbey,William M. Crist,L. Mao,G. Chen,C H Pui,M. Heim,F. Pedrosa +13 more
TL;DR: There was a striking predominance of the small noncleaved cell (Burkitt) subtype, which occurred in 92 of the 98 children and adolescents diagnosed with NHL, which may represent a third or intermediate subtype of Burkitt lymphoma.
•Journal Article
Clinical and biological heterogeneity of childhood B cell acute lymphocytic leukemia: implications for clinical trials.
Margaret P. Sullivan,D. J. Pullen,William M. Crist,Martin L. Brecher,Ramirez I,Sabio H,Michael J. Borowitz,David R. Head,Lizardo Cerezo,Jonathan J. Shuster +9 more
TL;DR: It is concluded that approximately 25% of children with B cell ALL are curable with intensive multiagent chemotherapy and that classification by immunophenotyping is superior to use of clinical and/or lymphoblast morphologic features.
Common solid tumors of childhood.
William M. Crist,Larry E. Kun +1 more
TL;DR: Enormous strides have been made in the management of malignant solid tumors since Farber first demonstrated the sensitivity of metastatic Wilms' tumor to dactinomycin in the mid-1960s; rates of cure for solid tumors have increased by as much as 50 percent; new histologic subtypes with implications for prognosis have been identified and incorporated into systems.
Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. A Pediatric Oncology Group Study.
Jan Van Eys,Jan Van Eys,Daisilee Berry,William M. Crist,Ed Doering,Donald J. Fernbach,Jeanette Pullen,J J Shuster +7 more
TL;DR: The overall remission rate was 94%, and event‐free survival at 8 years was 44% (SE, 5.6%).
Hereditary pyropoikilocytosis and elliptocytosis: clinical, laboratory, and ultrastructural features in infants and children.
TL;DR: Clinical, biochemical and ultrastructural assessment of five Black children from four unrelated kindreds, who had morphologic and laboratory features of hereditary pyropoikilocytosis (HP) is described, providing evidence for clinical and genetic heterogeneity of the pyroposynthetic phenotype.